NEW YORK, NY--(Marketwire - Nov 29, 2011) - According the World Health Organization, cancer will become the leading cause of death worldwide this year. Cancer has already emerged as the most expensive disease -- costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 million a year, it is clearly a lucrative sector for drug makers. The Bedford Report examines the outlook for companies in the biotechnology industry and provides investment research on Dendreon Corporation (NASDAQ: [ DNDN ]) and Human Genome Sciences, Inc. (NASDAQ: [ HGSI ]). Access to the full company reports can be found at:

[ www.bedfordreport.com/DNDN ]

[ www.bedfordreport.com/HGSI ]

Research from BioMed Tracker and BIO claims that the cancer drug success rate is a mere 4.7 percent. Upon revealing the study, the agency's Oncologic Drugs Advisory Committee endorsed several FDA proposals for tightening the accelerated approval standards.

Studies from the Friends of Cancer Research advocacy group find that new cancer drugs are approved in just six months on average in the United States -- half the time it takes for the same drugs to be approved in Europe. "When we realized we were correct, we thought, 'No one is going to believe us because this goes against urban legend,'" said Ellen V. Sigal, chairwoman and founder of Friends of Cancer Research.

User fees from the Prescription Drug User Fee Act of 1992 have helped provide the FDA with resources to shorten drug review times. The Act is up for reauthorization next year, and the Friends of Cancer Research argue that the speed of drug review times might not be as high a priority as achieving other objectives in advance regulatory science.

The Bedford Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at [ www.bedfordreport.com ] and get exclusive access to our numerous stock reports and industry newsletters.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. Shares of the company got a bump last week after it said that Medicare will reimburse doctors for administration costs associated with its prostate cancer therapy Provenge. Provenge is designed to train a patient's immune system to fight prostate cancer, and it is approved as a treatment for prostate cancer that hasn't responded to previous therapies. A round of treatment consists of three infusions and costs around $93,000.

Human Genome Sciences, Inc. operates as a biopharmaceutical company. Its principal products in development include BENLYSTA for systemic lupus erythematosus; and raxibacumab for inhalation anthrax. Earlier this year the company said it agreed with FivePrime Therapeutics Inc. to develop and bring to market a drug for treating several types of cancer. Under the terms of the agreement between the two companies, Human Genome Sciences received exclusive rights to develop and commercialize the drug in the U.S., Canada and European Union.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at [ http://www.bedfordreport.com/disclaimer ]